Testing Before Treating: Molecular Determinants of Optimal Therapy for NSCLC

Download All
Learn how experts test for biomarkers in patients with NSCLC with multidisciplinary perspectives from a medical oncologist and a pathologist, toward the optimal care of patients with NSCLC, including a downloadable slideset from the live webinar, a focused text-based module, and expert-authored commentaries on optimal biomarker testing to guide treatment for patients with NSCLC.
Matthew Gubens, MD, MS
Craig Mackinnon, MD, PhD

ClinicalThought

Expert commentary by Drs Matthew Gubens, a thoracic oncologist, and Craig Mackinnon, an anatomical and molecular pathologist, on the current and emerging role and importance of biomarker testing in NSCLC.

Matthew Gubens, MD, MS Craig Mackinnon, MD, PhD Released: July 11, 2022

Expert commentary by Matthew Gubens, MD, MS, a thoracic oncologist, and Craig Mackinnon, MD, PhD, an anatomical and molecular pathologist, on the recent FDA approval of trastuzumab deruxtecan for previously treated patients with HER2 mutation–positive advanced NSCLC.

Matthew Gubens, MD, MS Craig Mackinnon, MD, PhD Released: September 12, 2022

In this commentary, Drs Matthew Gubens, a thoracic oncologist, and Craig Mackinnon, an anatomical and molecular pathologist, address frequently asked questions about the importance of biomarker testing in NSCLC.

Matthew Gubens, MD, MS Craig Mackinnon, MD, PhD Released: August 31, 2022
Provided by Clinical Care Options, LLC in partnership with the Association for Molecular Pathology

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with
Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Genentech
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lilly
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings